Provided by Tiger Fintech (Singapore) Pte. Ltd.

Context Therapeutics Inc.

0.8387
-0.0309-3.55%
Post-market: 0.83870.00000.00%16:00 EDT
Volume:31.92K
Turnover:27.65K
Market Cap:75.23M
PE:-1.83
High:0.8979
Open:0.8561
Low:0.8353
Close:0.8696
Loading ...
Jun 05, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 30, 2024

Correspondence

Form CORRESP - Correspondence
May 24, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 13, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 10, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
May 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 02, 2024

Major Issues Report

Form 8-K - Current report
Apr 01, 2024

Major Issues Report

Form 8-K - Current report
Mar 21, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 21, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 21, 2024

Major Issues Report

Form 8-K - Current report
Mar 06, 2024

Major Issues Report

Form 8-K - Current report
Feb 13, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 07, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 05, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Nov 10, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 31, 2023

Major Issues Report

Form 8-K - Current report
Aug 09, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2023

Major Issues Report

Form 8-K - Current report
Jun 20, 2023

Major Issues Report

Form 8-K - Current report